<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438867</url>
  </required_header>
  <id_info>
    <org_study_id>CT-3-001</org_study_id>
    <nct_id>NCT00438867</nct_id>
  </id_info>
  <brief_title>Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization</brief_title>
  <acronym>AWARE</acronym>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Female Patients With Stable Angina Pectoris Who Are Not Candidates for Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardium Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardium Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a one-time intracoronary infusion of&#xD;
      Ad5FGF-4 is effective in reducing the time to onset myocardial ischemia as measured by&#xD;
      exercise treadmill testing and improving myocardial blood flow as measured by SPECT imaging.&#xD;
      Exercise capacity, angina functional class, patient symptoms and quality of life will also be&#xD;
      evaluated to characterize the efficacy of Ad5FGF-4. Short-term and long-term safety of&#xD;
      Ad5FGF-4 will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in time to onset of ECG changes diagnostic of myocardial ischemia during ETT</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in reversible perfusion defect size as measured by adenosine single-photon emission computed tomography with technetium-99m sestamibi (SPECT)(principal secondary endpoint)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total exercise treadmill time</measure>
    <time_frame>Months 3, 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in time to onset ECG changes diagnostic myocardial ischemia during ETT</measure>
    <time_frame>Months 3 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in time to onset of angina during ETT</measure>
    <time_frame>Months 3, 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in angina frequency and nitroglycerin</measure>
    <time_frame>Months 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient functional status using CCS angina class</measure>
    <time_frame>Months 3, 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rest and stress left ventricular ejection fraction assessed using gated SPECT</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life using the Seattle Angina Questionnaire</measure>
    <time_frame>Months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Ad5FGF-4 as assessed by adverse events and clinical laboratory testing</measure>
    <time_frame>Through month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term safety of Ad5FGF-4 as assessed by clinically important events</measure>
    <time_frame>Through month 60</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Ad5FGF-4</intervention_name>
    <description>Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control group</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients 18-75 years of age inclusive&#xD;
&#xD;
          -  Stable angina classified as CCS III or IV&#xD;
&#xD;
          -  Receiving treatment with at least two classes of chronic anti-anginal medication, of&#xD;
             which two are at the maximally tolerated dose&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) of ≥30%&#xD;
&#xD;
          -  Not a candidate for, or unlikely to benefit from standard revascularization procedures&#xD;
             as verified by an independent cardiologist or cardiothoracic surgeon (not a study&#xD;
             investigator) at each center&#xD;
&#xD;
          -  Can undergo ETT using the modified Bruce protocol and;&#xD;
&#xD;
               1. ECG changes diagnostic of myocardial ischemia occur during the first 10 minutes&#xD;
                  of exercise&#xD;
&#xD;
               2. Variability of the time to onset of ECG changes diagnostic of myocardial ischemia&#xD;
                  is ≤25% or within 60 seconds if the time to onset of myocardial ischemia occurs&#xD;
                  within the first 4 minutes of exercise as determined by two consecutive screening&#xD;
                  treadmill tests&#xD;
&#xD;
          -  Evidence of stress induced myocardial ischemia by adenosine SPECT, defined as a&#xD;
             reversible perfusion defect size of ≥9%&#xD;
&#xD;
          -  Willing and able to comply with the study requirements including long-term follow-up&#xD;
&#xD;
          -  Provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients of childbearing potential (must be surgically sterile or post-menopausal)&#xD;
&#xD;
          -  Patients for whom an immediate revascularization procedure is indicated (CABG surgery&#xD;
             or PCI)&#xD;
&#xD;
          -  Myocardial infarction within the past 3 months&#xD;
&#xD;
          -  Unstable angina or hospitalization requiring intravenous anti-anginal therapy within&#xD;
             the 14 days prior to the start of screening evaluations&#xD;
&#xD;
          -  Congestive heart failure NYHA Class IV&#xD;
&#xD;
          -  Electrocardiogram that precludes accurate assessment of exercise induced myocardial&#xD;
             ischemia (e.g., left bundle branch block, Wolf-Parkinson-White syndrome, atrial&#xD;
             fibrillation)&#xD;
&#xD;
          -  Myocarditis or restrictive pericarditis&#xD;
&#xD;
          -  Left main coronary stenosis ≥70% (unless the patient has a patent graft or collateral&#xD;
             vessels supplying the left coronary circulation) or proximal stenoses ≥70% in all&#xD;
             major coronary conduit vessels (coronary arteries and bypass grafts)&#xD;
&#xD;
          -  Clinically significant aortic or mitral valvular heart disease&#xD;
&#xD;
          -  Coronary ostial stenosis that precludes adequate catheter engagement in any target&#xD;
             vessel&#xD;
&#xD;
          -  Coronary artery to venous communications, which bypass the coronary capillary bed&#xD;
&#xD;
          -  Untreated life-threatening ventricular arrhythmias&#xD;
&#xD;
          -  CABG surgery within the past 6 months, unless those grafts are now occluded.&#xD;
&#xD;
          -  Percutaneous transluminal angioplasty (PTCA) within the past 3 months, unless the&#xD;
             dilated vessel(s) are now occluded&#xD;
&#xD;
          -  Enhanced external counterpulsation (EECP) within 3 months prior to the start of&#xD;
             screening evaluations&#xD;
&#xD;
          -  Transmyocardial or percutaneous myocardial laser revascularization within the previous&#xD;
             year&#xD;
&#xD;
          -  Prior treatment with any cardiovascular gene or stem cell therapy.&#xD;
&#xD;
          -  Any intercurrent illness that may interfere with their ability to perform a maximal&#xD;
             ETT&#xD;
&#xD;
          -  Any major organ disease that substantially impairs life expectancy.&#xD;
&#xD;
          -  History of cancer, other than basal cell carcinoma, or patients with any laboratory or&#xD;
             physical exam or diagnostic procedure finding suggestive of current malignancy&#xD;
&#xD;
          -  Moderate to severe nonproliferative or proliferative retinopathy from any cause (ETDRS&#xD;
             score &gt;35), clinically significant macular edema, or previous panretinal&#xD;
             photocoagulation therapy&#xD;
&#xD;
          -  Heparin induced thrombocytopenia or history of idiopathic thrombocytopenic purpura or&#xD;
             other medical condition causing thrombocytopenia&#xD;
&#xD;
          -  SGPT level greater than 2.0 times the upper limit of the laboratory normal range&#xD;
&#xD;
          -  Bilirubin level ≥2.0 mg/dL&#xD;
&#xD;
          -  Serum creatinine ≥2.5 mg/dL&#xD;
&#xD;
          -  Platelet count &lt;100,000/μL&#xD;
&#xD;
          -  White blood cell count &lt;3,000/μL&#xD;
&#xD;
          -  Positive test for hepatitis B or C&#xD;
&#xD;
          -  Positive test for HIV&#xD;
&#xD;
          -  History of colon cancer in a first degree relative (i.e., parent, sibling or&#xD;
             offspring) unless the patient has undergone a colonoscopy in the past 36 months with&#xD;
             negative findings&#xD;
&#xD;
          -  History of breast cancer in a first degree relative&#xD;
&#xD;
          -  Patient in a family with any documented hereditary cancer syndrome&#xD;
&#xD;
          -  Prior anaphylaxis reaction to iodinated contrast agents&#xD;
&#xD;
          -  Patients who are known to be immunosuppressed or are receiving chronic treatment with&#xD;
             immunosuppressive drugs&#xD;
&#xD;
          -  Received an investigational drug or biologic within 30 days of screening or are&#xD;
             currently participating in an investigational drug, biologic or device trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Engler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cardium Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Heart Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Heart</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Access Clinical Trials</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Internal Medical Group</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Denver Cardiology</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph's Research Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Idaho Cardiology Associates</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Valley Cardiovascular Consultants</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Heart Foundation</name>
      <address>
        <city>Lombard</city>
        <state>Illinois</state>
        <zip>60148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Research Alliance</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Care Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Duluth Clinic</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anthony's Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BryanLGH Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Heart &amp; Vascular Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Clinical Trial Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Ohio Heart Center</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cardiovascular Associates</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Heart &amp; Vascular Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heritage Cardiology Associates</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Clinic</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Stern Cardiovascular Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Cardiovascular Consultants</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Foundation</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>February 21, 2007</study_first_submitted>
  <study_first_submitted_qc>February 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2007</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>angina</keyword>
  <keyword>FGF-4</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>growth factor</keyword>
  <keyword>myocardia ischemia</keyword>
  <keyword>revascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

